scholarly journals In vitro and in vivo studies of temozolomide loading in zeolite structures as drug delivery systems for glioblastoma

RSC Advances ◽  
2015 ◽  
Vol 5 (36) ◽  
pp. 28219-28227 ◽  
Author(s):  
Olga Martinho ◽  
Natália Vilaça ◽  
Paulo J. G. Castro ◽  
Ricardo Amorim ◽  
António M. Fonseca ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cancer Cells ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
In Vivo Studies

Y and MOR zeolites were used as a host for the temozolomide (TMZ). Y presented toxicity to glioblastoma cancer cells in contrast to MOR. Higher potentiation of TMZ was obtained with MOR in comparison to free TMZ bothin vitroandin vivo.

Self-assembled drug delivery systems. Part 6: In vitro/in vivo studies of anticancer N-octadecanoyl gemcitabine nanoassemblies

2012 ◽  
Vol 430 (1-2) ◽  
pp. 276-281 ◽  
Author(s):  
Yiguang Jin ◽  
Yanju Lian ◽  
Lina Du ◽  
Shuangmiao Wang ◽  
Chang Su ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
In Vivo Studies ◽  
Self Assembled

Pegylated Drug Delivery Systems: From Design to Biomedical Applications

Nano LIFE ◽  
2016 ◽  
Vol 06 (03n04) ◽  
pp. 1642002 ◽  
Author(s):  
Fei Liu ◽  
Yuan Sun ◽  
Chen Kang ◽  
Hongyan Zhu
Keyword(s):  
Drug Delivery ◽  
Biomedical Applications ◽  
Drug Delivery Systems ◽  
Simple Procedure ◽  
Drug Carriers ◽  
Delivery Systems ◽  
Circulation Time ◽  
In Vivo Studies

Pegylation, as a simple procedure to attach hydrophilic polyethylene glycol (PEG) onto therapeutic molecule or drug carriers has been utilized widely to deliver small molecules, proteins and peptides. It was first reported in 1970s by Dr. Frank Davis of Rutgers University and Dr. Abuchowsky in the studies of PEG modified albumin and catalase. The significance of this method at that time was able to successfully modify the enzyme with better hydrophilicity but also keep the enzymatic activity. The employment of PEG has provided superior stability of drug delivery systems (DDS) and enhanced the circulation time in vivo. Simple conjugation of PEG chains with various molecular weights enables the possibility to regulate the properties of desired DDS and led to important contribution in targeting therapy and diagnosis. Pegylation has been reported to be able to protect peptides by shielding antigenic epitopes from reticuloendothelial (RES) clearance and avoid enzymes being recognized by immune system and avoid early degradation. In addition, utilization of PEG in DDS are reported with enhanced delivery efficiency, prolonged circulation time and improved stability, especially active enzymes and peptides drug delivery. In this paper, we will conclude current studies about Pegylated DDS and their biomedical applications from both in vitro and in vivo studies.

Nanoparticulate drug-delivery systems for fighting microbial biofilms: from bench to bedside

2020 ◽  
Vol 15 (8) ◽  
pp. 679-698 ◽  
Author(s):  
Gratiela G Pircalabioru ◽  
Mariana-Carmen Chifiriuc
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Antimicrobial Agents ◽  
Delivery Systems ◽  
In Vivo Studies ◽  
Microbial Biofilms ◽  
Adverse Environmental Conditions ◽  
The Many

Biofilms are highly tolerant to antimicrobial agents and adverse environmental conditions being important reservoirs for chronic and hard-to-treat infections. Nanomaterials exhibit microbiostatic/microbicidal/antipathogenic properties and can be also used for the delivery of antibiofilm agents. However, few of the many promising leads offered by nanotechnology reach clinical studies and eventually, become available to clinicians. The aim of this paper was to review the progress and challenges in the development of nanotechnology-based antibiofilm drug-delivery systems. The main identified challenges are: most papers report only in vitro studies of the activity of different nanoformulations; lack of standardization in the methodological approaches; insufficient collaboration between material science specialists and clinicians; paucity of in vivo studies to test efficiency and safety.

Transdermal Drug Delivery Systems of Albuterol: In Vitro and In Vivo Studies

1992 ◽  
Vol 81 (10) ◽  
pp. 996-999 ◽  
Author(s):  
Rajeev Gokhale ◽  
Cynthia Schmidt ◽  
Lisa Alcorn ◽  
James Stolzenbach ◽  
Grant Schoenhard ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Transdermal Drug Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
In Vivo Studies ◽  
Transdermal Drug Delivery Systems

scholarly journals Mechanisms and Pharmaceutical Action of Lipid Nanoformulation of Natural Bioactive Compounds as Efficient Delivery Systems in the Therapy of Osteoarthritis

Pharmaceutics ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1108
Author(s):  
Oana Craciunescu ◽  
Madalina Icriverzi ◽  
Paula Ecaterina Florian ◽  
Anca Roseanu ◽  
Mihaela Trif
Keyword(s):  
Drug Delivery ◽  
Bioactive Compounds ◽  
Targeted Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Joint Disease ◽  
Duration Of Action ◽  
Immune System Activation

Osteoarthritis (OA) is a degenerative joint disease. An objective of the nanomedicine and drug delivery systems field is to design suitable pharmaceutical nanocarriers with controllable properties for drug delivery and site-specific targeting, in order to achieve greater efficacy and minimal toxicity, compared to the conventional drugs. The aim of this review is to present recent data on natural bioactive compounds with anti-inflammatory properties and efficacy in the treatment of OA, their formulation in lipid nanostructured carriers, mainly liposomes, as controlled release systems and the possibility to be intra-articularly (IA) administered. The literature regarding glycosaminoglycans, proteins, polyphenols and their ability to modify the cell response and mechanisms of action in different models of inflammation are reviewed. The advantages and limits of using lipid nanoformulations as drug delivery systems in OA treatment and the suitable route of administration are also discussed. Liposomes containing glycosaminoglycans presented good biocompatibility, lack of immune system activation, targeted delivery of bioactive compounds to the site of action, protection and efficiency of the encapsulated material, and prolonged duration of action, being highly recommended as controlled delivery systems in OA therapy through IA administration. Lipid nanoformulations of polyphenols were tested both in vivo and in vitro models that mimic OA conditions after IA or other routes of administration, recommending their clinical application.

Sign in / Sign up

Export Citation Format

Share Document